Search results :

Atovaquone

More information: STITCH, PubChem and possibly Wikipedia

ATC Code: P01AX06

Side effects

Options: Hide MedDRA Preferred Terms

MedDRA Preferred Term Side effect Data for drug Placebo Labels
1 2 3
Headache Headache 16% - 31% x x x
Cough Cough increased 25% - 31% x x
Cough 1% - 14% x x x
Nausea Nausea 0.6% - 37% x x x
Infection Infection 18% - 22% x x
Diarrhoea Diarrhoea 0.2% - 42% x x x
Asthenia Asthenia 8% - 31% x x x
Body temperature increased Body temperature increased 0% - 40% x x x
Rhinitis Rhinitis 5% - 24% x x x
Dyspnoea Dyspnoea 15% - 21% x x
Insomnia Insomnia 10% - 19% x x x
Dermatitis Rash 4% - 46% x x x
Rash Rash 4% - 46% x x x
Hyperglycaemia Hyperglycaemia 9% - 13% x x x
Dysgeusia Dysgeusia 3% - 13% x x x
Abdominal pain Abdominal pain 4% - 21% x x x
Gastrointestinal pain Abdominal pain 4% - 21% x x x
Hypoglycaemia Hypoglycaemia 1% - 15.5% x x x
Vomiting Vomiting 1% - 22% x x x
Hyponatraemia Hyponatraemia 7% - 10% x x x
Pain Pain 9.86% - 10% x x x
Decreased appetite Anorexia 7% - 10% x x x
Anxiety Anxiety 7% - 10% x x x
Dyspepsia Dyspepsia 5% - 10% x x x
Hypotension Hypotension 1% - 10% x x x
Dizziness Dizziness 3% - 14.1% x x x
Blood alkaline phosphatase increased Phosphatase alkaline increased 8% x x
Amylase increased Amylase increased 4% - 8% x x x
Blood creatinine increased Creatinine increased 0% - 7% x x x
Sinusitis Sinusitis 5.63% - 7% x x x
Alanine aminotransferase increased Alanine aminotransferase increased 6% x x x
Hyperkalaemia Hyperkalaemia 0% - 5% x x x
Neutropenia Neutropenia 3% - 9% x x x
Pruritus Pruritus 5% x x x
Leukopenia Leukopenia 4% x x x
Aspartate aminotransferase increased Aspartate aminotransferase increased 0% - 5% x x x
Constipation Constipation 3% x x x
Anaemia Anaemia 0% - 9% x x x
Bronchospasm Bronchospasm postmarketing, 2% x x x
Hypersensitivity Hypersensitivity postmarketing, 0.8% - 4.8% x x x
Angioedema Angioedema postmarketing x x x
Erythema multiforme Erythema multiforme postmarketing x x
Stevens-Johnson syndrome postmarketing x x
Hepatitis Hepatitis postmarketing x x
Methaemoglobinaemia Methaemoglobinaemia postmarketing x x
Pancreatitis Pancreatitis postmarketing x x
Stevens-Johnson syndrome Stevens-Johnson syndrome postmarketing x x
Thrombocytopenia Thrombocytopenia postmarketing x x
Urticaria Urticaria postmarketing x x
Hepatic failure Hepatic failure postmarketing x x
Keratopathy Keratopathy postmarketing x x
Throat tightness Throat tightness postmarketing x x x
Skin exfoliation Skin exfoliation postmarketing x x
Renal failure Renal impairment postmarketing x x
Renal impairment Renal impairment postmarketing x x
Eye disorder Eye disorder x x
Gastrointestinal disorder Gastrointestinal disorder x x
Immune system disorder Immune system disorder x x
Influenza Influenza x x
Hyperhidrosis Sweating x x
Urethral disorder Urinary tract disorder x x
Urinary tract disorder Urinary tract disorder x x
Skin disorder Unspecified disorder of skin and subcutaneous tissue x x
Myalgia Myalgia x x
Musculoskeletal discomfort Myalgia x x
Hepatobiliary disease Hepatobiliary disease x x
Laboratory test abnormal Laboratory test abnormal x x x

Indications

Information about indications was extracted from the indications and usage sections of the labels.

ATOVAQUONE / MEPRON

Side effects:37
Source:Health Canada

ATOVAQUONE

Side effects:62
Source:FDA Structured Product Label

ATOVAQUONE

Side effects:62
Source:FDA Structured Product Label

Color scheme:

standard – alternative

    100%
    75%
    50%
    10%
    frequent (1% to 100%)
    infrequent (0.1% to 1%)
    rare (<0.1%)
    postmarketing
    0%
    no frequency information
    not found on label